TABLE 5.
Analysis of cytokines in preclinical studies in vivo.
| Mean ± SD | std.Mean difference [95%CI] | p value | ||
|---|---|---|---|---|
| Study | ||||
| E | C | |||
| ELISA | p = 0.03 | |||
| 5.1 IL-17 | ||||
| Jain, et al., 2016 | 0.20 ± 0.07 | 0.42 ± 0.01 | −2.16 [−3.89, −0.42] | |
| Nan, et al., 2020 | 1.36 ± 0.15 | 1.63 ± 0.38 | −0.86 [−2.07, 0.34] | |
| Total (95% CI) Random-effects I2 = 30% | −1.35 [−2.58, −0.12] | |||
| 5.2 TNF-α | p = 0.02 | |||
| Jain, et al., 2016 | 0.42 ± 0.33 | 1.04 ± 0.15 | −2.18 [−3.93, −0.44] | |
| Nan, et al., 2020 | 20.86 ± 2.00 | 33.50 ± 2.53 | −5.40 [−6.98, −3.83] | |
| Total (95% CI) Random-effects I2 = 86% | −3.82 [−6.97, −0.66] | |||
| RT-PCR | ||||
| 5.3 IL-17F | p = 0.01 | |||
| Sun, et al., 2017 | 0.57 ± 0.32 | 20.19 ± 6.29 | −4.07 [−6.35,−1.78] | |
| Zhang, et al., 2019 | 13.59 ± 2.87 | 20.69 ± 3.87 | −1.81 [−3.68, 0.05] | |
| Total (95% CI) Random-effects I2 = 55% | −2.84 [−5.04, −0.64] | |||
| 5.4 IL-22 | p = 0.003 | |||
| Sun, et al., 2017 | 0.20 ± 0.25 | 4.52 ± 1.58 | −3.53 [−5.59, −1.47] | |
| Zhang, et al., 2019 | 20.16 ± 6.32 | 98.49 ± 12.53 | −6.86 [−11.78, −1.94] | |
| Total (95% CI) Random-effects I2 = 34% | −4.42 [−7.31, −1.52] | |||
| 5.5 TNF-α | p = 0.49 | |||
| Sun, et al., 2017 | 0.90 ± 0.40 | 0.14 ± 0.41 | 1.73 [0.32, 3.14] | |
| Zhang, et al., 2019 | 9.38 ± 2.77 | 86.48 ± 5.99 | −14.37 [−24.35, −4.39] | |
| Total (95% CI) Random-effects I2 = 90% | −5.53 [−21.23, 10.17] | |||
Abbrevations: IL, interleukin; TNF, tumor necrosis factor; E, experimental group; C, control group.